Strides Pharma Science Ltd
Strides Pharma Science Ltd is in the business of development and manufacturing of pharmaceutical products.[1] The company's pharmaceutical products are sold in over 100 countries.[2]
The company has always followed an inorganic growth strategy over the years that resulted in foray into new markets, addition of new business segments, therapy segments and manufacturing infrastructure.[3]
- Market Cap ₹ 7,751 Cr.
- Current Price ₹ 843
- High / Low ₹ 865 / 325
- Stock P/E
- Book Value ₹ 223
- Dividend Yield 0.18 %
- ROCE -0.23 %
- ROE -8.36 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 3.77 times its book value
- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -0.39%
- The company has delivered a poor sales growth of 5.33% over past five years.
- Promoter holding is low: 27.4%
- Company has a low return on equity of -2.79% over last 3 years.
- Promoters have pledged 69.2% of their holding.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Dec 2011 | Dec 2012 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2,550 | 962 | 1,341 | 1,196 | 2,861 | 2,755 | 2,845 | 2,178 | 2,752 | 3,316 | 3,070 | 3,688 | 3,953 | |
2,111 | 861 | 1,567 | 967 | 2,486 | 2,228 | 2,448 | 1,982 | 2,351 | 2,779 | 3,201 | 3,544 | 3,452 | |
Operating Profit | 439 | 101 | -226 | 229 | 374 | 527 | 398 | 197 | 401 | 537 | -131 | 145 | 501 |
OPM % | 17% | 10% | -17% | 19% | 13% | 19% | 14% | 9% | 15% | 16% | -4% | 4% | 13% |
133 | 959 | 3,281 | 874 | 63 | 291 | 643 | 303 | -30 | 109 | -112 | 92 | -54 | |
Interest | 195 | 79 | 109 | 47 | 168 | 183 | 196 | 79 | 156 | 150 | 177 | 261 | 315 |
Depreciation | 104 | 31 | 56 | 64 | 131 | 126 | 154 | 117 | 174 | 206 | 233 | 243 | 232 |
Profit before tax | 273 | 949 | 2,890 | 992 | 137 | 509 | 690 | 303 | 42 | 289 | -653 | -268 | -99 |
Tax % | 14% | 11% | 39% | 15% | 31% | 12% | 1% | -9% | 27% | 11% | 27% | 21% | |
234 | 847 | 1,767 | 844 | 95 | 446 | 684 | 330 | 31 | 258 | -474 | -212 | -119 | |
EPS in Rs | 38.44 | 143.92 | 296.43 | 141.78 | 12.15 | 44.71 | 74.25 | 36.25 | 4.06 | 29.93 | -51.25 | -22.44 | -10.98 |
Dividend Payout % | 5% | 1% | 170% | 76% | 41% | 10% | 3% | 8% | 345% | 8% | 0% | -7% |
Compounded Sales Growth | |
---|---|
10 Years: | 14% |
5 Years: | 5% |
3 Years: | 10% |
TTM: | 11% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 91% |
Stock Price CAGR | |
---|---|
10 Years: | 6% |
5 Years: | 12% |
3 Years: | -2% |
1 Year: | 159% |
Return on Equity | |
---|---|
10 Years: | 18% |
5 Years: | 1% |
3 Years: | -3% |
Last Year: | -8% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Dec 2011 | Dec 2012 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 58 | 59 | 60 | 60 | 89 | 89 | 90 | 90 | 90 | 90 | 90 | 90 | 90 |
Reserves | 1,313 | 1,967 | 947 | 1,085 | 2,569 | 2,659 | 2,374 | 2,559 | 2,438 | 2,687 | 2,269 | 2,105 | 1,963 |
2,643 | 1,594 | 547 | 892 | 3,542 | 3,700 | 2,520 | 3,221 | 2,235 | 2,348 | 3,025 | 3,030 | 2,795 | |
1,341 | 1,175 | 543 | 438 | 1,211 | 1,598 | 1,601 | 1,937 | 1,369 | 1,844 | 1,556 | 1,369 | 1,490 | |
Total Liabilities | 5,355 | 4,796 | 2,096 | 2,475 | 7,410 | 8,046 | 6,585 | 7,807 | 6,131 | 6,969 | 6,940 | 6,594 | 6,338 |
3,188 | 3,017 | 555 | 701 | 2,679 | 2,980 | 2,977 | 3,648 | 2,099 | 2,219 | 2,347 | 2,311 | 1,992 | |
CWIP | 285 | 241 | 99 | 171 | 815 | 780 | 620 | 453 | 413 | 447 | 291 | 151 | 46 |
Investments | 0 | 0 | 443 | 630 | 1,341 | 1,525 | 588 | 702 | 549 | 697 | 540 | 490 | 416 |
1,882 | 1,538 | 999 | 972 | 2,576 | 2,762 | 2,400 | 3,005 | 3,070 | 3,605 | 3,762 | 3,642 | 3,885 | |
Total Assets | 5,355 | 4,796 | 2,096 | 2,475 | 7,410 | 8,046 | 6,585 | 7,807 | 6,131 | 6,969 | 6,940 | 6,594 | 6,338 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Dec 2011 | Dec 2012 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
457 | 139 | -272 | 83 | 73 | 288 | 187 | 60 | 205 | 481 | -258 | 44 | |
-659 | 771 | 4,044 | 50 | -2,205 | -1,222 | 570 | -145 | 1,321 | -522 | -119 | 302 | |
89 | -990 | -3,319 | -421 | 2,944 | 338 | -1,016 | 194 | -1,709 | -16 | 421 | -214 | |
Net Cash Flow | -113 | -80 | 454 | -288 | 812 | -596 | -259 | 110 | -184 | -56 | 45 | 133 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Dec 2011 | Dec 2012 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 77 | 183 | 99 | 119 | 132 | 132 | 113 | 165 | 124 | 122 | 144 | 129 |
Inventory Days | 139 | 328 | 90 | 135 | 149 | 209 | 146 | 294 | 254 | 329 | 285 | 257 |
Days Payable | 169 | 344 | 137 | 153 | 188 | 221 | 188 | 299 | 259 | 311 | 260 | 220 |
Cash Conversion Cycle | 47 | 168 | 52 | 102 | 92 | 120 | 71 | 160 | 119 | 140 | 168 | 165 |
Working Capital Days | -106 | 18 | 53 | -29 | 96 | 63 | 117 | 155 | 95 | 116 | 210 | 156 |
ROCE % | 11% | 27% | 113% | 57% | 8% | 11% | 16% | 6% | 5% | 8% | -5% | -0% |
Documents
Announcements
- Compliance Certificate For FY 2024 11 Apr
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
9 Apr - Strides receives USFDA approval for Fluoxetine Tabs 10 mg and 20 mg
- Completion Of US-FDA Inspection At The Formulations Facility Of Strides Alathur Private Limited, A Wholly Owned Subsidiary Of The Company 6 Apr
-
Announcement under Regulation 30 (LODR)-Acquisition
29 Mar - Consolidate Strides, South Africa with Trinity Pharma, South Africa, larger step-down subsidiary of Strides group
-
Announcement under Regulation 30 (LODR)-Diversification / Disinvestment
29 Mar - Revision in business model in Latin America
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Concalls
-
Feb 2024Transcript PPT REC
-
Nov 2023Transcript PPT
-
Oct 2023TranscriptPPT
-
Aug 2023TranscriptPPT
-
Jun 2023Transcript PPT
-
Feb 2023TranscriptPPT
-
Nov 2022TranscriptPPT
-
Aug 2022TranscriptPPT
-
Jun 2022TranscriptPPT
-
Aug 2021TranscriptPPT
-
May 2021TranscriptPPT
-
Feb 2021TranscriptPPT
-
Oct 2020TranscriptPPT
-
Aug 2020TranscriptPPT
-
May 2020TranscriptPPT
-
Jan 2020TranscriptPPT
-
Dec 2019TranscriptPPT
-
Jul 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Jan 2019TranscriptPPT
-
Aug 2018TranscriptPPT
-
May 2018TranscriptPPT
-
Feb 2018TranscriptPPT
-
Oct 2017TranscriptPPT
-
Aug 2017TranscriptPPT
-
May 2017TranscriptPPT
-
Feb 2017TranscriptPPT
-
Oct 2016TranscriptPPT
-
Aug 2016TranscriptPPT
-
May 2016TranscriptPPT
-
Feb 2016TranscriptPPT
About[1]
Incorporated in 1990, Strides operates in the pharmaceutical industry, manufacturing generic formulations in various dosage forms.